Health - Resources and discussion for everything health-related

2455 readers

307 users here now

Health: physical and mental, individual and public.

Discussions, issues, resources, news, everything.

See the pinned post for a long list of other communities dedicated to health or specific diagnoses. The list is continuously updated.

Nothing here shall be taken as medical or any other kind of professional advice.

Commercial advertising is considered spam and not allowed. If you're not sure, contact mods to ask beforehand.

Linked videos without original description context by OP to initiate healthy, constructive discussions will be removed.

Regular rules of lemmy.world apply. Be civil.

founded 2 years ago

MODERATORS

Awa

WhoRoger

RoyalEngineering

Class action filed against Johnson & Johnson over 'ineffective' flu medication (www.abc.net.au)

submitted 3 weeks ago by MicroWave to c/health

2 comments fedilink hide all child comments

Summary

A class action lawsuit has been filed in Australia against Johnson & Johnson, accusing the company of misleading consumers by selling cold and flu medications with phenylephrine, an ineffective oral nasal congestion ingredient.

Products like Codral PE and Sudafed PE replaced pseudoephedrine with phenylephrine in 2006 after stricter regulations.

Lawyers argue consumers were “duped” into buying ineffective products at premium prices.

If successful, buyers since 2005 could be compensated. The TGA is monitoring FDA findings but has no current plans to review oral phenylephrine’s effectiveness.

top 2 comments

sorted by: hot top controversial new old

[–] [email protected] 4 points 3 weeks ago (1 children)

Why the shit won't TGA take FDA's findings into account? There is no significant genetic difference between the populations... Am I missing something here?

[–] ForgotAboutDre 3 points 3 weeks ago

It’s normal for these types of agencies to make their own judgments, they shouldn’t assume the FDA knows better. Population and genetic differences shouldn’t matter and won’t be a factor.